JP7284830B2 - タンパク質チロシンホスファターゼ阻害剤 - Google Patents

タンパク質チロシンホスファターゼ阻害剤 Download PDF

Info

Publication number
JP7284830B2
JP7284830B2 JP2021558566A JP2021558566A JP7284830B2 JP 7284830 B2 JP7284830 B2 JP 7284830B2 JP 2021558566 A JP2021558566 A JP 2021558566A JP 2021558566 A JP2021558566 A JP 2021558566A JP 7284830 B2 JP7284830 B2 JP 7284830B2
Authority
JP
Japan
Prior art keywords
mmol
tert
butyl
dihydrospiro
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021558566A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020201991A5 (https=
JP2022527796A (ja
JP2022527796A5 (https=
Inventor
エフ．ブレイク ジェイムズ
ローレンス ボーイズ マーク
ジョセフ チカレッリ マーク
ダブリュ．クック アダム
エス．エー．エルセイド モハメッド
ブラッドフォード フェール ジェイ
ピー．フィッシャー ジョン
ジェイ ヒンクリン ロナルド
ジャン ユートン
ティー．マックナルティ オーレン
ジェイ．メヒア マセドニオ
イー．ロドリゲス マーサ
イー．ウォン クリスティーナ
Original Assignee
アレイ バイオファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレイ バイオファーマ インコーポレイテッド filed Critical アレイ バイオファーマ インコーポレイテッド
Publication of JP2022527796A publication Critical patent/JP2022527796A/ja
Publication of JPWO2020201991A5 publication Critical patent/JPWO2020201991A5/ja
Publication of JP2022527796A5 publication Critical patent/JP2022527796A5/ja
Priority to JP2023049681A priority Critical patent/JP2023078421A/ja
Application granted granted Critical
Publication of JP7284830B2 publication Critical patent/JP7284830B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021558566A 2019-04-02 2020-03-30 タンパク質チロシンホスファターゼ阻害剤 Active JP7284830B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023049681A JP2023078421A (ja) 2019-04-02 2023-03-27 タンパク質チロシンホスファターゼ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962828356P 2019-04-02 2019-04-02
US62/828,356 2019-04-02
US202062992558P 2020-03-20 2020-03-20
US62/992,558 2020-03-20
PCT/IB2020/053019 WO2020201991A1 (en) 2019-04-02 2020-03-30 Protein tyrosine phosphatase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023049681A Division JP2023078421A (ja) 2019-04-02 2023-03-27 タンパク質チロシンホスファターゼ阻害剤

Publications (4)

Publication Number Publication Date
JP2022527796A JP2022527796A (ja) 2022-06-06
JPWO2020201991A5 JPWO2020201991A5 (https=) 2022-09-02
JP2022527796A5 JP2022527796A5 (https=) 2022-09-02
JP7284830B2 true JP7284830B2 (ja) 2023-05-31

Family

ID=70277430

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558566A Active JP7284830B2 (ja) 2019-04-02 2020-03-30 タンパク質チロシンホスファターゼ阻害剤
JP2023049681A Pending JP2023078421A (ja) 2019-04-02 2023-03-27 タンパク質チロシンホスファターゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023049681A Pending JP2023078421A (ja) 2019-04-02 2023-03-27 タンパク質チロシンホスファターゼ阻害剤

Country Status (26)

Country Link
US (3) US11634417B2 (https=)
EP (1) EP3947367A1 (https=)
JP (2) JP7284830B2 (https=)
KR (1) KR102698608B1 (https=)
CN (1) CN113874363B (https=)
AU (1) AU2020251841B2 (https=)
BR (1) BR112021018664A2 (https=)
CA (1) CA3135555C (https=)
CL (2) CL2021002542A1 (https=)
CO (1) CO2021013030A2 (https=)
CR (1) CR20210501A (https=)
CU (1) CU20210080A7 (https=)
DO (1) DOP2021000206A (https=)
EC (1) ECSP21072994A (https=)
GE (2) GEP20237561B (https=)
IL (2) IL320682A (https=)
MA (1) MA55511A (https=)
MX (1) MX2021012122A (https=)
PE (1) PE20220141A1 (https=)
PH (1) PH12021552227A1 (https=)
PY (1) PY2018672A (https=)
SG (1) SG11202110502PA (https=)
TW (1) TWI766261B (https=)
UY (1) UY38628A (https=)
WO (1) WO2020201991A1 (https=)
ZA (1) ZA202108443B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023078421A (ja) * 2019-04-02 2023-06-06 アレイ バイオファーマ インコーポレイテッド タンパク質チロシンホスファターゼ阻害剤

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
US12187721B2 (en) 2018-10-17 2025-01-07 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
JP7599039B2 (ja) * 2021-03-23 2024-12-12 上海海雁医薬科技有限公司 複素環置換ケトン類誘導体、その組成物および医薬における使用
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
CN117083285A (zh) * 2021-03-31 2023-11-17 南京明德新药研发有限公司 一系列含Se的吡嗪类化合物及其应用
CN117460725A (zh) * 2021-04-01 2024-01-26 阵列生物制药公司 Shp2抑制剂的晶型
CA3215295A1 (en) * 2021-04-01 2022-10-06 Array Biopharma Inc. Crystalline form of a shp2 inhibitor
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
TW202244049A (zh) * 2021-05-12 2022-11-16 大陸商藥雅科技（上海）有限公司 Shp2磷酸酶抑制劑的製備及其應用
CN115960109B (zh) * 2021-05-31 2024-06-25 药雅科技(上海)有限公司 稠环类shp2磷酸酶抑制剂的制备及其应用
CA3226206A1 (en) 2021-07-09 2023-01-12 Kanaph Therapeutics Inc. Shp2 inhibitor and use thereof
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
EP4417600A4 (en) * 2021-10-14 2025-02-19 Beijing Tide Pharmaceutical Co., Ltd. SHP2 INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
JP2025509818A (ja) 2022-03-23 2025-04-11 アレイ バイオファーマ インコーポレイテッド Ｓｈｐ２阻害剤の結晶性塩形態
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
WO2024218632A1 (en) 2023-04-17 2024-10-24 Array Biopharma Inc. Erk protein kinase inhibitors
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502994A (ja) 2014-01-17 2017-01-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
WO2018013597A1 (en) 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
JP2018517752A (ja) 2015-06-19 2018-07-05 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
WO2018172984A1 (en) 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
RU2629116C2 (ru) 2011-10-14 2017-08-24 Эррэй Биофарма Инк. Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
AR092253A1 (es) 2012-08-27 2015-04-08 Array Biopharma Inc Inhibidores de serina/treonina cinasa
DK3053923T3 (en) 2013-09-30 2018-07-23 Korea Res Inst Chemical Tech TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS
JP6523303B2 (ja) 2014-01-17 2019-05-29 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2824576T3 (es) 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
AU2017274199B2 (en) 2016-05-31 2021-09-23 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
MX383856B (es) 2016-06-14 2025-03-14 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2.
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
MX2019008696A (es) 2017-01-23 2019-09-13 Revolution Medicines Inc Compuestos de piridina como inhibidores de shp2 alostericos.
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
WO2018218133A1 (en) 2017-05-26 2018-11-29 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
WO2019051469A1 (en) 2017-09-11 2019-03-14 Krouzon Pharmaceuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
EP3687997A1 (en) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
MX2020003579A (es) 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
US11426422B2 (en) 2018-01-30 2022-08-30 Research Development Foundation SHP2 inhibitors and methods of use thereof
RU2020133727A (ru) 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
SG11202009245TA (en) 2018-03-21 2020-10-29 Relay Therapeutics Inc Shp2 phosphatase inhibitors and methods of use thereof
WO2019183364A1 (en) 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
LT3833670T (lt) 2018-08-10 2024-06-25 Navire Pharma, Inc. 6-(4-amino-3-metil-2-oksa-8-azaspiro[4.5]dekan-8-il)-3-(2,3-dichlorfenil)-2-metilpirimidin-4(3h)-ono dariniai ir susiję junginiai kaip ptpn11 (shp2) inhibitoriai, skirti vėžiui gydyti
CN112839935A (zh) * 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
US12187721B2 (en) 2018-10-17 2025-01-07 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
WO2020201991A1 (en) * 2019-04-02 2020-10-08 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502994A (ja) 2014-01-17 2017-01-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
JP2018517752A (ja) 2015-06-19 2018-07-05 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
WO2018013597A1 (en) 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
WO2018172984A1 (en) 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JORGE GARCIA FORTANET; ET AL，ALLOSTERIC INHIBITION OF SHP2: IDENTIFICATION OF A POTENT, SELECTIVE, AND ORALLY 以下備考，JOURNAL OF MEDICINAL CHEMISTRY，2016年07月12日，VOL:59, NR:17，PAGE(S):7773-7782，http://dx.doi.org/10.1021/acs.jmedchem.6b00680，EFFICACIOUS PHOSPHATASE INHIBITOR
PAOLA CIAPETTI; ET AL，CHAPTER 15 - MOLECULAR VARIATIONS BASED ON ISOSTERIC REPLACEMENTS，THE PRACTICE OF MEDICINAL CHEMISTRY，NL，ELSEVIER，2008年，PAGE(S):290-342，http://dx.doi.org/10.1016/B978-0-12-374194-3.00015-9

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023078421A (ja) * 2019-04-02 2023-06-06 アレイ バイオファーマ インコーポレイテッド タンパク質チロシンホスファターゼ阻害剤

Also Published As

Publication number Publication date
GEAP202315746A (en) 2023-07-10
PH12021552227A1 (en) 2022-05-30
GEP20237561B (en) 2023-10-25
BR112021018664A2 (pt) 2021-11-23
US20240124453A1 (en) 2024-04-18
TW202102490A (zh) 2021-01-16
WO2020201991A1 (en) 2020-10-08
JP2022527796A (ja) 2022-06-06
MX2021012122A (es) 2021-11-03
ZA202108443B (en) 2023-04-26
AU2020251841B2 (en) 2025-01-30
CU20210080A7 (es) 2022-05-11
CA3135555A1 (en) 2020-10-08
SG11202110502PA (en) 2021-10-28
US20220251083A1 (en) 2022-08-11
PY2018672A (es) 2021-09-24
CA3135555C (en) 2023-09-19
US20200317665A1 (en) 2020-10-08
EP3947367A1 (en) 2022-02-09
UY38628A (es) 2020-10-30
ECSP21072994A (es) 2021-11-18
MA55511A (fr) 2022-02-09
KR20210146389A (ko) 2021-12-03
CO2021013030A2 (es) 2021-10-20
CN113874363A (zh) 2021-12-31
JP2023078421A (ja) 2023-06-06
CL2021002542A1 (es) 2022-06-24
US11884664B2 (en) 2024-01-30
CL2024000183A1 (es) 2024-06-07
IL286462A (en) 2021-10-31
TWI766261B (zh) 2022-06-01
US11634417B2 (en) 2023-04-25
CR20210501A (es) 2021-11-02
DOP2021000206A (es) 2021-11-21
AU2020251841A1 (en) 2021-10-07
CN113874363B (zh) 2024-11-12
IL320682A (en) 2025-07-01
KR102698608B1 (ko) 2024-08-27
PE20220141A1 (es) 2022-01-27

Similar Documents

Publication Publication Date Title
JP7284830B2 (ja) タンパク質チロシンホスファターゼ阻害剤
US12187721B2 (en) Protein tyrosine phosphatase inhibitors
JP6878615B2 (ja) Ｓｈｐ２阻害剤として有用な新規な複素環式誘導体
KR101961500B1 (ko) 세린/트레오닌 키나제 억제제
CN108699065A (zh) 作为激酶抑制剂的三环类化合物和组合物
RU2799449C2 (ru) Ингибиторы протеинтирозинфосфатазы
RU2780532C1 (ru) Ингибиторы протеинтирозинфосфатазы
EA047856B1 (ru) Ингибиторы протеинтирозинфосфатазы
HK40057282A (en) Protein tyrosine phosphatase inhibitors
OA20546A (en) Protein tyrosine phosphatase inhibitors.
HK40057282B (zh) 蛋白质酪氨酸磷酸酶抑制剂
HK40062341A (en) Protein tyrosine phosphatase inhibitors
EA047802B1 (ru) Ингибиторы протеинтирозинфосфатазы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220818

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230327

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230327

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230404

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230405

C272 Notice of ex officio correction

Free format text: JAPANESE INTERMEDIATE CODE: C272

Effective date: 20230405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230519

R150 Certificate of patent or registration of utility model

Ref document number: 7284830

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150